Poisson

Business as usual: bank climate commitments, lending, and engagement

Retrieved on: 
tisdag, april 2, 2024
Smoke, Carbon, Pillar, Worldwide, BPER, Employment, Disclosure, Economic methodology, LEI, Research Papers in Economics, CGD, Ibercaja Banco, Fossil, Mediobanca, Policy, UNEP, Crédit Mutuel, BBVA, Columbia Business School, Pari, Corporate finance, NBER, Principle, Agriculture, Société Générale, Insurance, Allied Irish Banks, Medical classification, Aluminium, Becker, Feedback, Central bank, Triodos Bank, Target, Prosocial behavior, Journal of Financial Economics, European Parliament, MIT, R2, Website, Behavior, Poisson, Human, UN, Climate, Crédit Agricole, United Nations, Transport, Coal mining, Syndicated loan, Investment, ABN AMRO, Politics, BSI, OLS, PDF, ECB, Unemployment, Econometrics, Ambition, Clutch (eggs), IEA, Social science, Engagement, JEL, Climate change, Risk management, Yb, Bias, Abanca, Research, Classification, UniCredit, A.5, NZIA, Divestment, Literature, IPCC, European Central Bank, AA, Geography, Natural gas, Green lending, Metal, The Borrowers, Elasticity, Stanford Social Innovation Review, Steven M. Greer, BMPS, Finance, Risk, Single, CaixaBank, PPML, BNP Paribas, European, Money, NLB Group, La Banque postale, Corporate welfare, Paris Agreement, A.2, ROW, OECD, Fraud, Coal, Frustration, Iron, Commerzbank, Bank of Åland, COP, Comparison, Overalls, All, Temperature, Banca Ifis, Conference, Pressure, Steel, International Energy Agency, United, Alpha Bank, Interest, SSRN, Justice, AAA, Deutsche Bank, Crawford, Science Based Targets initiative, GFANZ, Quarterly Journal, Rabobank, Hirschman, Effect, Carbon Disclosure Project, ESG, MSCI, Support, NZBA, Sierra Club, Map, Taxonomy, Q50, Banco Sabadell, Financial Times, Banco BPM, BPCE, Reproduction, Erste Group, Data, G21, Interval (mathematics), Cardboard
Key Points: 

    GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons

    Retrieved on: 
    onsdag, juni 21, 2023
    Other Health, Research, General Health, Pharmaceutical, Consumer, Infectious Diseases, Clinical Trials, Science, Biotechnology, Seniors, FDA, Health, ACIP, GSK, US Foods, Public, Poisson, CI, Season, Arthralgia, CDC, RSV, Myalgia, Risk, Stockholm Environment Institute US Center, Headache, III, Food, Fatigue, Vaccine

    The trial also evaluated efficacy following an annual revaccination schedule as a confirmatory secondary endpoint.

    Key Points: 
    • The trial also evaluated efficacy following an annual revaccination schedule as a confirmatory secondary endpoint.
    • The clinical development program will continue to evaluate longer term follow up and the optimal timing for potential revaccination.
    • Tony Wood, Chief Scientific Officer, GSK, said: “Our goal is to provide a high level of protection for older adults most at risk from RSV.
    • These data will be submitted to the US Food and Drug Administration (FDA) and other regulators for review.

    Kiboko Gold Drills Multiple High-grade Intervals Including 8.7 g/t Au Over 9 m and 23.9 g/t Au Over 3 m at its Harricana Gold Project

    Retrieved on: 
    torsdag, januari 26, 2023
    Mining, Minerals, Natural Resources, Amos, Bias, Laboratory, Poisson, Honours degree, Gold, Abitibi greenstone belt, Project, Security (finance), National instrument, Accreditation, NI, Nature, MSA, News, Exploration, Hyperaccumulators table – 3, Bunkhouse, Harricana River, Poisson distribution, Hyperaccumulators table – 2 : Nickel, QA/QC, Abitibi, Multimedia, Geology, Technical report, RC, Engineered wood, Road, Uranium mining, Palladium

    As shown in figures 1 and 2, the Harricana Project (the “Project” or “Harricana Project”) is located 55 kilometres north of Val-d’Or, Québec, in the world-renowned Abitibi gold belt.

    Key Points: 
    • As shown in figures 1 and 2, the Harricana Project (the “Project” or “Harricana Project”) is located 55 kilometres north of Val-d’Or, Québec, in the world-renowned Abitibi gold belt.
    • To date, 2 holes (totalling 540 m of drilling) have been completed as part of the Company’s ongoing 12-hole / 2,800 m winter diamond drilling program.
    • In addition to intercepting several exciting high-grade intervals, many lower grade intervals were intersected in this first batch of assay results.
    • Further investigation is necessary, including the study of gold grain size distribution, gold content, and representative sub-sample sizes for assaying is necessary.

    Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-submit Following Additional Data Analyses

    Retrieved on: 
    fredag, augusti 13, 2021
    Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, McNeil Consumer Healthcare, Clinical trial, Muscle, MOVE, Observation, Phase, United, Safety, Review, Research and development, Neglected tropical disease research and development, Company, Food, United Kingdom, FDA, Degenerative disease, New Drug Application, IPN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fibrodysplasia ossificans progressiva, Orphanet Journal of Rare Diseases, Tendon, Prevalence, IDMC, Patent, NDA, Risk, PPC, Priority review, ADR, Heterotopic ossification, Heart, HO, Acquisition, Poisson, FOP, Patient, Development, Star Trek: Phase II, Pharmaceutical industry

    Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following very recent discussions with the U.S. Food and Drug Administration (FDA), withdrawal of the New Drug Application (NDA) for palovarotene.

    Key Points: 
    • Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following very recent discussions with the U.S. Food and Drug Administration (FDA), withdrawal of the New Drug Application (NDA) for palovarotene.
    • As a result, Ipsen has therefore confirmed their withdrawal of the NDA for palovarotene.
    • After recent discussion with FDA, Ipsen plans to resubmit to the FDA upon completion of the additional data analyses.
    • The target regulatory action date assigned by the FDA under a Priority Review status for palovarotene was 30 November 2021.